ELRIG are delighted to announce that Dr. Ian Tomlinson of Apollo Therapeutics will be the plenary keynote speaker for day one of Research & Innovation 2017, to be held at Homerton College, Cambridge on 29th and 30th March.
Ian is Chairman of the Board of the Stevenage Biosciences Catalyst, Chairman of the Investment Committee for Apollo Therapeutics, sits on the Board of the UK BioIndustry Association, and is part of the Major Awards Committee for the UK’s Biomedical Catalyst funding scheme.
The Stevenage Bioscience Catalyst is the UK’s first open innovation biomedical campus. where fast growing biotech, pharma and medtech businesses can draw upon world-leading expertise, networks, academic support and scientific facilities. Based close to big pharma on the London-Cambridge corridor it offers access to equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies.
Apollo Therapeutics is a £40 million fund, launched in January 2016, with the goal of significantly improving the speed and potential of university research being translated into novel medicines. It is a unique collaboration between AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation, and the technology transfer offices of Imperial College London, University College London and the University of Cambridge, and is the first time that global pharmaceutical companies and world-leading universities have come together to create this type of fund.
For further information or to register for Research & Innovation 2017, visit the event web page by clicking here.